News & Media
Following approval of shareholders, companies sign German transfer agreement
Curetis GmbH and its subsidiaries Curetis USA Inc. and Ares Genetics GmbH are now wholly owned by OpGen, Inc.
OpGen consideration shares to be distributed to Curetis N.V. shareholders and Curetis N.V. to be dissolved and delisted from Euronext
Three Curetis N.V. Supervisory Board members resign to join newly formed OpGen Inc. board of directors
Rapid real-time PCR test allows testing for SARS-CoV2 in only a few hours
Test kit to be made available via Curetis’ European sales channels
Synergies with Curetis Unyvero HPN panel for pneumonia testing for bacterial co-infections in Covid-19 patients
Curetis N.V. reports that a Special Meeting of shareholders of OpGen, Inc. held today, March 10, 2020, in Washington DC, USA, to approve the business combination of Curetis and OpGen, was adjourned.
Feb 03 – Curetis Expands Commercial Team
trial of its antibiotic solithromycin (CEM-101)
Upcoming Events 2020